| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0950-3536(96)80041-2 |
| P8608 | Fatcat ID | release_qo4hkeeoubacvilu63u3vjvys4 |
| P698 | PubMed publication ID | 8730555 |
| P2093 | author name string | Löwenberg B | |
| P2860 | cites work | Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B | Q28247684 |
| Susceptibility of acute myeloid leukemia (AML) cells from clinically resistant and sensitive patients to daunomycin (DNR): assessment in vitro after stimulation with colony stimulating factors (CSFs). | Q34553480 | ||
| Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. | Q34722375 | ||
| On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group | Q35155166 | ||
| Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia | Q36776247 | ||
| Acute myeloid leukaemia in the elderly: biology and treatment | Q40485001 | ||
| Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial | Q44029830 | ||
| A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group | Q45244768 | ||
| Hematopoiesis and aging III: Anemia and a blunted erythropoietic response to hemorrhage in aged mice | Q49194086 | ||
| Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. | Q52882178 | ||
| Population-based age- and sex-specific incidence rates in the 4 main types of leukaemia. | Q55062877 | ||
| PROGNOSTIC VALUE OF CD34 EXPRESSION IN DE NOVO ACUTE MYELOBLASTIC LEUKAEMIA | Q61479700 | ||
| Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (My10) | Q67677506 | ||
| Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia | Q67780734 | ||
| Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly | Q70369165 | ||
| P433 | issue | 1 | |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 147-159 | |
| P577 | publication date | 1996-03-01 | |
| P1433 | published in | Best Practice and Research: Clinical Haematology | Q15755888 |
| P1476 | title | Treatment of the elderly patient with acute myeloid leukaemia | |
| P478 | volume | 9 |
| Q38820155 | 7-formyl-10-methylisoellipticine, a novel ellipticine derivative, induces mitochondrial reactive oxygen species (ROS) and shows anti-leukaemic activity in mice |
| Q39395720 | Acute myelocytic leukemia (M0) in an elderly patient with relapsed granulocytic sarcoma (M7) of bone during the second period of complete remission 5 years after onset |
| Q34334070 | Acute myeloid leukemia in the elderly: biology and therapeutic strategies. |
| Q43622754 | Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial |
| Q38967701 | Ellipticine derivative induces potent cytostatic effect in acute myeloid leukaemia cells |
| Q40138696 | Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years. |
| Q34320192 | Managing therapy in older adult patients with acute myeloid leukemia |
| Q83857352 | Outcomes and quality of care in acute myeloid leukemia over 40 years |
| Q77170469 | Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS |
| Q34383226 | Recent advances in the treatment of AML. |
| Q38132064 | The evolving landscape in the therapy of acute myeloid leukemia |
| Q38143696 | The role of protein conformational switches in pharmacology: its implications in metabolic reprogramming and protein evolution |
| Q35291847 | Treatment concepts for elderly patients with acute myeloid leukemia. |
| Q34781362 | Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cells |
| Q39342733 | Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape |
Search more.